US Stock MarketDetailed Quotes

CTXRW Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com)

Watchlist
  • 0.0000
  • 0.00000.00%
Close Dec 23 09:30 ET
0Market Cap0.00P/E (TTM)

About Citius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com) Company

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Company Profile

SymbolCTXRW
Company NameCitius Pharmaceuticals Inc C/Wts 00/00/2022 (To Pur Com)
CEOMr. Leonard L. Mazur
MarketNASDAQ
Employees10

Company Executives

  • Name
  • Position
  • Salary
  • Leonard L. Mazur
  • Chairman of the Board and Chief Executive Officer
  • --
  • Dr. Myron Czuczman
  • Chief Medical Officer and Executive Vice President
  • --
  • Jaime Bartushak
  • Chief Financial Officer, Chief Accounting Officer and Chief Business Officer
  • --
  • Michael McGuire
  • Vice President and Program Leader for Anti-Infectives
  • --
  • Myron Z. Holubiak
  • Executive Vice Chairman of the Board
  • --
  • Howard Safir
  • Lead Independent Director
  • --
  • Dr. Eugene Holuka
  • Independent Director
  • --
  • Carol Webb
  • Independent Director
  • --
  • Suren G. Dutia
  • Independent Director
  • --
  • Dr. William Kane
  • Independent Director
  • --
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.